MX2021014074A - Agonistas de receptor de melanocortina-4. - Google Patents

Agonistas de receptor de melanocortina-4.

Info

Publication number
MX2021014074A
MX2021014074A MX2021014074A MX2021014074A MX2021014074A MX 2021014074 A MX2021014074 A MX 2021014074A MX 2021014074 A MX2021014074 A MX 2021014074A MX 2021014074 A MX2021014074 A MX 2021014074A MX 2021014074 A MX2021014074 A MX 2021014074A
Authority
MX
Mexico
Prior art keywords
compound
present
melanocortin
receptor agonists
activity against
Prior art date
Application number
MX2021014074A
Other languages
English (en)
Inventor
Eun Sil Choi
Seung Wan Kang
Ji Ho Hong
Hee Dong Park
Park, (Mismo Nombre Que Inventor Anterior Diferente Persona) Hee Dong
Su Jin Yeo
Hyun Seo Park
Hye Won Ahn
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2021014074A publication Critical patent/MX2021014074A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona a un compuesto que exhibe excelente actividad agonista contra los receptores de melanocortina. Más específicamente, la presente invención se relaciona a un compuesto de la Fórmula 1, una composición farmacéutica que comprende el compuesto como un ingrediente activo, y un uso del mismo, y el compuesto de la presente invención exhibe excelente actividad agonista contra los receptores de melacortina-4 y puede ser particularmente útil en prevenir o tratar obesidad, diabetes, inflamación y disfunción eréctil.
MX2021014074A 2019-11-07 2020-11-06 Agonistas de receptor de melanocortina-4. MX2021014074A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190141649 2019-11-07
PCT/KR2020/015462 WO2021091283A1 (en) 2019-11-07 2020-11-06 Melanocortin-4 receptor agonists

Publications (1)

Publication Number Publication Date
MX2021014074A true MX2021014074A (es) 2021-12-10

Family

ID=75848091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014074A MX2021014074A (es) 2019-11-07 2020-11-06 Agonistas de receptor de melanocortina-4.

Country Status (25)

Country Link
US (1) US20220289731A1 (es)
EP (1) EP3953327B1 (es)
JP (2) JP7467510B2 (es)
KR (1) KR102485182B1 (es)
CN (1) CN113939500A (es)
AU (1) AU2020377805B2 (es)
BR (1) BR112021022497A2 (es)
CA (1) CA3135543C (es)
CL (1) CL2021003409A1 (es)
CO (1) CO2021017401A2 (es)
DK (1) DK3953327T3 (es)
ES (1) ES2970510T3 (es)
FI (1) FI3953327T3 (es)
HU (1) HUE064968T2 (es)
IL (1) IL288921A (es)
MX (1) MX2021014074A (es)
PE (1) PE20220766A1 (es)
PL (1) PL3953327T3 (es)
PT (1) PT3953327T (es)
SG (1) SG11202112163XA (es)
SI (1) SI3953327T1 (es)
TW (1) TWI754448B (es)
UA (1) UA127255C2 (es)
WO (1) WO2021091283A1 (es)
ZA (1) ZA202110474B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023004731A (es) * 2020-10-29 2023-05-10 Lg Chemical Ltd Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma.
JP2023548163A (ja) * 2020-10-29 2023-11-15 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の結晶形ｉｉおよびその製造方法
TWI823169B (zh) * 2020-10-29 2023-11-21 南韓商Ｌｇ化學股份有限公司 黑皮質素受體促效劑化合物的晶形ⅲ及其製備方法
JP2023548327A (ja) * 2020-10-29 2023-11-16 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の結晶形ｉおよびその製造方法
JP2023548162A (ja) * 2020-10-29 2023-11-15 エルジー・ケム・リミテッド 無定形のメラノコルチン－４受容体アゴニスト
JP2024500906A (ja) * 2020-12-22 2024-01-10 エルジー・ケム・リミテッド 無定形のメラノコルチン受容体アゴニストおよびその製造方法
CN116635033A (zh) * 2020-12-22 2023-08-22 株式会社Lg化学 黑皮质素受体激动剂化合物的结晶形式iii及其制备方法
JP2024501828A (ja) * 2020-12-22 2024-01-16 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の結晶形ｉｉおよびその製造方法
CN116782877A (zh) * 2020-12-22 2023-09-19 株式会社Lg化学 作为黑皮质素-4受体的选择性激动剂的用途
EP4249483A4 (en) * 2020-12-22 2024-05-15 Lg Chemical Ltd CRYSTALLINE FORM I OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR THE PREPARATION THEREOF
AU2022209657A1 (en) * 2021-01-21 2023-07-20 Lg Chem, Ltd. Uses of melanocortin-4 receptor agonist
JP2024508469A (ja) * 2021-02-26 2024-02-27 エルジー・ケム・リミテッド メラノコルチン－４受容体アゴニスト
AU2022269993A1 (en) * 2021-05-06 2023-11-02 Lg Chem, Ltd. Crystal form vii of melanocortin receptor agonist compound and method for preparing same
EP4317149A1 (en) * 2021-05-06 2024-02-07 Lg Chem, Ltd. Crystalline form v of melanocortin receptor agonist compound, and method for preparing same
BR112023022432A2 (pt) * 2021-05-07 2024-01-09 Lg Chemical Ltd Formas cristalinas iv de sais de ácidos orgânicos de composto agonista do receptor de melanocortina, seus metódos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas
BR112023022334A2 (pt) * 2021-05-07 2023-12-26 Lg Chemical Ltd Formas cristalinas de sulfato do composto agonista do receptor de melanocortina, seus métodos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas
EP4321512A1 (en) * 2021-05-07 2024-02-14 Lg Chem, Ltd. Co-crystal of melanocortin receptor agonist compound and vanillin and method for preparing same
KR20230120106A (ko) * 2022-02-08 2023-08-16 주식회사 엘지화학 멜라노코르틴-4 수용체 효능제의 희귀성 유전적 비만질환의 예방 또는 치료에서의 용도
TW202345798A (zh) * 2022-03-28 2023-12-01 南韓商Ｌｇ化學股份有限公司 預防或治療肥胖的聯合療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4929601A (en) * 2000-03-23 2001-10-03 Merck & Co Inc Substituted piperidines as melanocortin receptor agonists
GB0019359D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
EP1383501B1 (en) 2001-02-28 2007-04-04 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
AR044510A1 (es) 2003-04-14 2005-09-14 Merck & Co Inc Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina
WO2005047251A1 (en) * 2003-11-12 2005-05-26 Lg Life Sciences Ltd. Melanocortin receptor agonists
TWI332501B (en) * 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
TWI669301B (zh) 2014-05-29 2019-08-21 日商田邊三菱製藥股份有限公司 新穎吡咯啶化合物及作爲黑皮質素受體促效藥之用途
MX2023004731A (es) * 2020-10-29 2023-05-10 Lg Chemical Ltd Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma.

Also Published As

Publication number Publication date
CN113939500A (zh) 2022-01-14
ES2970510T3 (es) 2024-05-29
BR112021022497A2 (pt) 2022-05-17
DK3953327T3 (da) 2024-02-05
PT3953327T (pt) 2024-02-05
JP2024028542A (ja) 2024-03-04
CL2021003409A1 (es) 2022-08-19
CO2021017401A2 (es) 2022-04-08
EP3953327A1 (en) 2022-02-16
ZA202110474B (en) 2023-09-27
UA127255C2 (uk) 2023-06-21
PE20220766A1 (es) 2022-05-16
SG11202112163XA (en) 2021-12-30
IL288921A (en) 2022-02-01
JP2022548452A (ja) 2022-11-21
HUE064968T2 (hu) 2024-04-28
PL3953327T3 (pl) 2024-05-06
WO2021091283A1 (en) 2021-05-14
AU2020377805A1 (en) 2021-11-25
JP7467510B2 (ja) 2024-04-15
SI3953327T1 (sl) 2024-04-30
TWI754448B (zh) 2022-02-01
EP3953327B1 (en) 2023-12-27
CA3135543A1 (en) 2021-05-14
US20220289731A1 (en) 2022-09-15
AU2020377805B2 (en) 2023-02-02
KR20210055624A (ko) 2021-05-17
CA3135543C (en) 2023-08-01
FI3953327T3 (fi) 2024-01-31
TW202128681A (zh) 2021-08-01
EP3953327A4 (en) 2022-06-29
KR102485182B1 (ko) 2023-01-06

Similar Documents

Publication Publication Date Title
ZA202110474B (en) Melanocortin-4 receptor agonists
EA201170676A1 (ru) Агонисты рецептора меланокортина
MX2020011562A (es) Agonistas del receptor de la hormona tiroidea y usos de los mismos.
NI201700073A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2009006304A (es) Nuevos compuestos de oxadiazol.
EA202190377A1 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
CL2008003847A1 (es) Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad.
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
CL2011000795A1 (es) Compuestos derivados de n-(1,3,4-tiadiazol-2-il) aril/heteroaril-amida, agonistas del receptor de 1-fosfato de esfingosina; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratammiento de enfermedades autoinmunes, inflamatorias cronicas, rechazo de transplantes, dolor, entre otras.
MX2019006600A (es) Agonistas duales de glp-1/glp-2.
PH12017501424B1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EA029499B9 (ru) Ингибиторы rorc2 и способы их применения
PH12020551656A1 (en) Growth differentiation factor 15 agonist compounds and methods of using the same
MY197464A (en) Aza-indazole compounds for use in tendon and/or ligament injuries
CL2015003286A1 (es) (ciano-dimetil-metil)-(isoxazoles y -[1, 3, 4] tiadiazoles novedosos
MX2021005944A (es) Inhibidores de rip1.
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
EA201290905A1 (ru) Бензазепиновое соединение
MX2017015047A (es) Compuestos que tienen actividad antagonista del receptor muscarinico y actividad agonista del receptor beta2 adrenergico.
EP4238966A4 (en) TETRAHYDRONAPHTHALIN COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
WO2017168414A8 (en) Iron chelators and combination thereof for the treatment of wolfram syndrome 2
MX2022006903A (es) Productos orales con irritacion reducida.
NZ750150A (en) Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors
MX2019001698A (es) Combinacion triple de agonistas inversos del receptor de histamina 3, inhibidores de la acetilcolinestearasa y antagonistas del receptor nmda.
WO2012083397A8 (en) Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis